Estrogens and epithelial ovarian cancer

Gynecologic Oncology

Volumn 94, Issue 1, 2004, Pages 25-32

  Cunat, Séverine ^a,b   Hoffmann, Pascale ^b,c   Pujol, Pascal ^a,b  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b INSERM   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Estrogen receptors; Estrogens; Ovarian cancer; Tumor progression

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; BRCA1 PROTEIN; CATHEPSIN D; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FIBULIN; GESTAGEN; KALLIKREIN; MYC PROTEIN; PROGESTERONE RECEPTOR; PROTEIN PS2; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; DISEASE MARKER; DRUG EFFICACY; ESTROGEN THERAPY; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HIGH RISK PATIENT; HUMAN; ONCOGENE; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; TUMOR GROWTH;

CELL DIVISION; DISEASE PROGRESSION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; OVARIAN NEOPLASMS; RECEPTORS, ESTROGEN;

EID: 3242728753     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.03.026     Document Type: Article

References (108)

1. Greenlee R.T., Murray T., Bolden S., Wingo P.A. Cancer statistics, 2000. CA Cancer J. Clin. 50:2000;7-33
2. Katso R.M., Manek S., O'Byrne K., Playford M.P., Le Meuth V., Ganesan T.S. Molecular approaches to diagnosis and management of ovarian cancer. Cancer Metastasis Rev. 16:1997;81-107
3. Auersperg N., Wong A.S., Choi K.C., Kang S.K., Leung P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22:2001;255-288
4. Weiss N.S., Lyon J.L., Krishnamurthy S., Dietert S.E., Liff J.M., Daling J.R. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J. Natl. Cancer Inst. 68:1982;95-98
5. Booth M., Beral V., Smith P. Risk factors for ovarian cancer: a case-control study. Br. J. Cancer. 60:1989;592-598
6. Purdie D., Green A., Bain C., Siskind V., Ward B., Hacker N., et al. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group. Int. J. Cancer. 62:1995;678-684
7. Hempling R.E., Wong C., Piver M.S., Natarajan N., Mettlin C.J. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet. Gynecol. 89:1997;1012-1016
8. Purdie D.M., Bain C.J., Siskind V., Russell P., Hacker N.F., Ward B.G., et al. Hormone replacement therapy and risk of epithelial ovarian cancer. Br. J. Cancer. 81:1999;559-563
9. Parazzini F., La Vecchia C., Negri E., Villa A. Estrogen replacement therapy and ovarian cancer risk. Int. J. Cancer. 57:1994;135-136
10. Risch H.A. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol. Oncol. 63:1996;254-257
11. Hunt K., Vessey M., McPherson K., Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br. J. Obstet. Gynaecol. 94:1987;620-635
12. Adami H.O., Persson I., Hoover R., Schairer C., Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int. J. Cancer. 44:1989;833-839
13. Rodriguez C., Calle E.E., Coates R.J., Miracle-McMahill H.L., Thun M.J., Heath C.W. Jr. Estrogen replacement therapy and fatal ovarian cancer. Am. J. Epidemiol. 141:1995;828-835
14. Rodriguez C., Patel A.V., Calle E.E., Jacob E.J., Thun M.J. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA. 285:2001;1460-1465
15. Lacey J.V. Jr., Mink P.J., Lubin J.H., Sherman M.E., Troisi R., Hartge P., et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 288:2002;334-341
16. Riman T., Dickman P.W., Nilsson S., Correia N., Nordlinder H., Magnusson C.M., et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J. Natl. Cancer Inst. 94:2002;497-504
17. Coughlin S.S., Giustozzi A., Smith S.J., Lee N.C. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J. Clin. Epidemiol. 53:2000;367-375
18. Garg P.P., Kerlikowske K., Subak L., Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet. Gynecol. 92:1998;472-479
19. Negri E., Tzonou A., Beral V., Lagiou P., Trichopoulos D., Parazzini F., et al. Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int. J. Cancer. 80:1999;848-851
20. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333
21. Anderson G.L., Judd H.L., Kaunitz A.M., Barad D.H., Beresford S.A., Pettinger M., et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA. 290:2003;1739-1748
22. Rao B.R., Slotman B.J. Endocrine factors in common epithelial ovarian cancer. Endocr. Rev. 12:1991;14-26
23. Hatch K.D., Beecham J.B., Blessing J.A., Creasman W.T. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer. 68:1991;269-271
24. Perez-Gracia J.L., Carrasco E.M. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol. Oncol. 84:2002;201-209
25. Hillier S.G., Anderson R.A., Williams A.R., Tetsuka M. Expression of oestrogen receptor alpha and beta in cultured human ovarian surface epithelial cells. Mol. Hum. Reprod. 4:1998;811-815
26. Pujol P., Rey J.M., Nirde P., Roger P., Gastaldi M., Laffargue F., et al. Differential expression of estrogen receptor-alpha and-beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res. 58:1998;5367-5373
27. Lau K.M., Mok S.C., Ho S.M. Expression of human estrogen receptor-alpha and-beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 96:1999;5722-5727
28. Brandenberger A.W., Tee M.K., Jaffe R.B. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. J. Clin. Endocrinol. Metab. 83:1998;1025-1028
29. Langdon S.P., Hirst G.L., Miller E.P., Hawkins R.A., Tesdale A.L., Smyth J.F., et al. The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. J. Steroid Biochem. Mol. Biol. 50:1994;131-135
30. Galtier-Dereure F., Capony F., Maudelonde T., Rochefort H. Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. J. Clin. Endocrinol. Metab. 75:1992;1497-1502
31. Nash J.D., Ozols R.F., Smyth J.F., Hamilton T.C. Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro. Obstet. Gynecol. 73:1989;1009-1016
32. Kuiper G.G., Gustafsson J.A. The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett. 410:1997;87-90
33. Mosselman S., Polman J., Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 392:1996;49-53
34. Rutherford T., Brown W.D., Sapi E., Aschkenazi S., Munoz A., Mor G. Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet. Gynecol. 96:2000;417-421
35. Roger P., Sahla M.E., Makela S., Gustafsson J.A., Baldet P., Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 61:2001;2537-2541
36. Leygue E., Dotzlaw H., Watson P.H., Murphy L.C. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res. 58:1998;3197-3201
37. Iwao K., Miyoshi Y., Egawa C., Ikeda N., Noguchi S. Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers. Int. J. Cancer. 88:2000;733-736
38. Pasquali D., Rossi V., Esposito D., Abbondanza C., Puca G.A., Bellastella A., et al. Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J. Clin. Endocrinol. Metab. 86:2001;2051-2055
39. Pasquali D., Staibano S., Prezioso D., Franco R., Esposito D., Notaro A., et al. Estrogen receptor beta expression in human prostate tissue. Mol. Cell. Endocrinol. 178:2001;47-50
40. Latil A., Bieche I., Vidaud D., Lidereau R., Berthon P., Cussenot O., et al. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 61:2001;1919-1926
41. Horvath L.G., Henshall S.M., Lee C.S., Head D.R., Quinn D.I., Makela S., et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res. 61:2001;5331-5335
42. Stabile L.P., Davis A.L., Gubish C.T., Hopkins T.M., Luketich J.D., Christie N., et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res. 62:2002;2141-2150
43. Foley E.F., Jazaeri A.A., Shupnik M.A., Jazaeri O., Rice L.W. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res. 60:2000;245-248
44. Campbell-Thompson M., Lynch I.J., Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res. 61:2001;632-640
45. Lazennec G., Bresson D., Lucas A., Chauveau C., Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology. 142:2001;4120-4130
46. Cavailles V., Garcia M., Rochefort H. Regulation of cathepsin-D and pS2 gene expression by growth factors in MCF7 human breast cancer cells. Mol. Endocrinol. 3:1989;552-558
47. Hayashido Y., Lucas A., Rougeot C., Godyna S., Argraves W.S., Rochefort H. Estradiol and fibulin-1 inhibit motility of human ovarian- and breast-cancer cells induced by fibronectin. Int. J. Cancer. 75:1998;654-658
48. Rochefort H., Platet N., Hayashido Y., Derocq D., Lucas A., Cunat S., et al. Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview. J. Steroid Biochem. Mol. Biol. 65:1998;163-168
49. Twal W.O., Czirok A., Hegedus B., Knaak C., Chintalapudi M.R., Okagawa H., et al. Fibulin-1 suppression of fibronectin-regulated cell adhesion and motility. J. Cell Sci. 114:2001;4587-4598
50. Rochefort H., Chalbos D., Cunat S., Lucas A., Platet N., Garcia M. Estrogen regulated proteases and antiproteases in ovarian and breast cancer cells. J. Steroid Biochem. Mol. Biol. 76:2001;119-124
51. Clinton G.M., Hua W. Estrogen action in human ovarian cancer. Crit. Rev. Oncol./Hematol. 25:1997;1-9
52. Yousef G.M., Diamandis E.P. Kallikreins, steroid hormones and ovarian cancer: is there a link? Minerva Endocrinol. 27:2002;157-166
53. Montgomery B.T., Young C.Y., Bilhartz D.L., Andrews P.E., Prescott J.L., Thompson N.F., et al. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate. 21:1992;63-73
54. Horwitz K.B., Koseki Y., McGuire W.L. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology. 103:1978;1742-1751
55. Hamilton T.C., Young R.C., Louie K.G., Behrens B.C., McKoy W.M., Grotzinger K.R., et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res. 44:1984;5286-5290
56. Kommoss F., Pfisterer J., Thome M., Geyer H., Sauerbrei W., Pfleiderer A. Estrogen and progesterone receptors in ovarian neoplasms: discrepant results of immunohistochemical and biochemical results. Int. J. Gynecol. Cancer. 1:1991;147-153
57. Kommoss F., Pfisterer J., Thome M., Schafer W., Sauerbrei W., Pfleiderer A. Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecol. Oncol. 47:1992;317-322
58. Masiakowski P., Breathnach R., Bloch J., Gannon F., Krust A., Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res. 10:1982;7895-7903
59. Nunez A.M., Jakowlev S., Briand J.P., Gaire M., Krust A., Rio M.C., et al. Characterization of the estrogen-induced pS2 protein secreted by the human breast cancer cell line MCF-7. Endocrinology. 121:1987;1759-1765
60. Foekens J.A., Rio M.C., Seguin P., van Putten W.L., Fauque J., Nap M., et al. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res. 50:1990;3832-3837
61. Wysocki S.J., Hahnel E., Masters A., Smith V., McCartney A.J., Hahnel R. Detection of pS2 messenger RNA in gynecological cancers. Cancer Res. 50:1990;1800-1802
62. Henry J.A., Bennett M.K., Piggott N.H., Levett D.L., May F.E., Westley B.R. Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br. J. Cancer. 64:1991;677-682
63. Watson P.H., Pon R.T., Shiu R.P. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res. 51:1991;3996-4000
64. Schuchard M., Landers J.P., Sandhu N.P., Spelsberg T.C. Steroid hormone regulation of nuclear proto-oncogenes. Endocr. Rev. 14:1993;659-669
65. Baker V.V., Borst M.P., Dixon D., Hatch K.D., Shingleton H.M., Miller D. c-myc amplification in ovarian cancer. Gynecol. Oncol. 38:1990;340-342
66. Schreiber G., Dubeau L. C-myc proto-oncogene amplification detected by polymerase chain reaction in archival human ovarian carcinomas. Am. J. Pathol. 137:1990;653-658
67. Watson J.V., Curling O.M., Munn C.F., Hudson C.N. Oncogene expression in ovarian cancer: a pilot study of c-myc oncoprotein in serous papillary ovarian cancer. Gynecol. Oncol. 28:1987;137-150
68. Polacarz S.V., Hey N.A., Stephenson T.J., Hill A.S. C-myc oncogene product P62c-myc in ovarian mucinous neoplasms: immunohistochemical study correlated with malignancy. J. Clin. Pathol. 42:1989;148-152
69. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712
70. Zhang X., Silva E., Gershenson D., Hung M.C. Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract. Oncogene. 4:1989;985-989
71. Kury F.D., Schneeberger C., Sliutz G., Kubista E., Salzer H., Medl M., et al. Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation. Oncogene. 5:1990;1403-1408
72. Haldane J.S., Hird V., Hughes C.M., Gullick W.J. c-erbB-2 oncogene expression in ovarian cancer. J. Pathol. 162:1990;231-237
73. Mandai M., Konishi I., Koshiyama M., Mori T., Arao S., Tashiro H., et al. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression. Cancer Res. 54:1994;1825-1830
74. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:1990;4087-4091
75. Smith V., Hobbs S., Court W., Eccles S., Workman P., Kelland L.R. ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. Anticancer Res. 22:2002;1993-1999
76. Read L.D., Keith D. Jr., Slamon D.J., Katzenellenbogen B.S. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res. 50:1990;3947-3951
77. Dati C., Antoniotti S., Taverna D., Perroteau I., De Bortoli M. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene. 5:1990;1001-1006
78. Russell K.S., Hung M.C. Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res. 52:1992;6624-6629
79. Hua W., Christianson T., Rougeot C., Rochefort H., Clinton G.M. SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. J. Steroid Biochem. Mol. Biol. 55:1995;279-289
80. Clinton G.M., Rougeot C., Derancourt J., Roger P., Defrenne A., Godyna S., et al. Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc. Natl. Acad. Sci. U. S. A. 93:1996;316-320
81. Roger P., Pujol P., Lucas A., Baldet P., Rochefort H. Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors. Am. J. Pathol. 153:1998;1579-1588
82. Moll F., Katsaros D., Lazennec G., Hellio N., Roger P., Giacalone P.L., et al. Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells. Oncogene. 21:2002;1097-1107
83. Gottardis M.M., Robinson S.P., Satyaswaroop P.G., Jordan V.C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48:1988;812-815
84. Scambia G., Benedetti P., Ferrandina G., Battaglia F., Baiocchi G., Mancuso S. Cathepsin D assay in ovarian cancer: correlation with pathological features and receptors for oestrogen, progesterone and epidermal growth factor. Br. J. Cancer. 64:1991;182-184
85. Scambia G., Panici P.B., Ferrandina G., Salerno G., D'Agostino G., Distefano M., et al. Clinical significance of cathepsin D in primary ovarian cancer. Eur. J. Cancer. 30A:1994;935-940
86. Baekelandt M., Holm R., Trope C.G., Nesland J.M., Kristensen G.B. The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer. Ann. Oncol. 10:1999;1335-1341
87. Lösch A., Scindl M., Kohlberger P., Lahodny J., Breitenecker G., Horvat R., et al. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol. Oncol. 92:2004;545-552
88. Clements J., Hooper J., Dong Y., Harvey T. The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions. Biol. Chem. 382:2001;5-14
89. Myers S.A., Clements J.A. Kallikrein 4 (KLK4), a new member of the human kallikrein gene family is up-regulated by estrogen and progesterone in the human endometrial cancer cell line, KLE. J. Clin. Endocrinol. Metab. 86:2001;2323-2326
90. Dong Y., Kaushal A., Bui L., Chu S., Fuller P.J., Nicklin J., et al. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin. Cancer Res. 7:2001;2363-2371
91. Luo L.Y., Katsaros D., Scorilas A., Fracchioli S., Beccino R., van Grahberen H., et al. The serum concentration of human kallikrein-10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res. 63:2003;807-811
92. Yousef G.M., Kyriakopoulou L.G., Scorilas A., Fracchioli S., Ghiringhello B., Zarghooni M., et al. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res. 61:2001;7811-7818
93. Anzick S.L., Kononen J., Walker R.L., Azorsa D.O., Tanner M.M., Guan X.Y., et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 277:1997;965-968
94. Tanner M.M., Grenman S., Koul A., Johannsson O., Meltzer P., Pejovic T., et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin. Cancer Res. 6:2000;1833-1839
95. Havrilesky L.J., McMahon C.P., Lobenhofer E.K., Whitaker R., Marks J.R., Berchuck A. Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones. J. Soc. Gynecol. Investig. 8:2001;104-113
96. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:1994;66-71
97. Merajver S.D., Pham T.M., Caduff R.F., Chen M., Poy E.L., Cooney K.A., et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat. Genet. 9:1995;439-443
98. Fan S., Wang J., Yuan R., Ma Y., Meng Q., Erdos M.R., et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science. 284:1999;1354-1356
99. Park J.J., Irvine R.A., Buchanan G., Koh S.S., Park J.M., Tilley W.D., et al. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res. 60:2000;5946-5949
100. Okubo T., Mok S.C., Chen S. Regulation of aromatase expression in human ovarian surface epithelial cells. J. Clin. Endocrinol. Metab. 85:2000;4889-4899
101. Hinshelwood M.M., Smith M.E., Murry B.A., Mendelson C.R. A 278 bp region just upstream of the human CYP19 (aromatase) gene mediates ovary-specific expression in transgenic mice. Endocrinology. 141:2000;2050-2053
102. Thompson M.A., Adelson M.D., Kaufman L.M., Marshall L.D., Coble D.A. Aromatization of testosterone by epithelial tumor cells cultured from patients with ovarian carcinoma. Cancer Res. 48:1988;6491-6497
103. Sasano H., Harada N. Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr. Rev. 19:1998;593-607
104. Zimniski S.J., Garola R.E., Fendl K., Peterson C.M. Endocrine characterization of a human ovarian carcinoma (BG-1) established in nude mice. Steroids. 54:1989;593-606
105. Blomquist C.H., Leung B.S., Zhang R., Zhu Y., Chang P.M. Properties and regulation of 17 beta-hydroxysteroid oxidoreductase of OVCAR-3, CAOV-3, and A431 cells: effects of epidermal growth factor, estradiol, and progesterone. J. Cell. Biochem. 59:1995;409-417
106. Thijssen J.H., Daroszewski J., Milewicz A., Blankenstein M.A. Local aromatase activity in human breast tissues. J. Steroid Biochem. Mol. Biol. 44:1993;577-582
107. Miller W.R., Anderson T.J., Dixon J.M. Anti-tumor effects of letrozole. Cancer Invest. 20(Suppl. 2):2002;15-21
108. Bowman A., Gabra H., Langdon S.P., Lessells A., Stewart M., Young A., et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin. Cancer Res. 8:2002;2233-2239